What is claimed is:

1. A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount of an anti-C3b(i) antibody.

2. A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount a nucleic acid sequence encoding an anti-C3b(i) antibody.

3. The method of Claim 1 or 2 in which the anti-C3b(i) antibody is immunospecific specific for C3b(i) covalently linked to IgM or IgG antibody on cancer cells.

4. The method of Claim 1 or 2 in which the anti-C3b(i) antibody is immunospecific for C3b(i) covalently linked to proteins or lipids on cancer cells.

5. The method of Claim 1 or 2 in which the anti-C3b(i) antibody is a bispecific antibody which is immunospecific for C3b(i) and an effector cell receptor or antigen.

6. The method of Claim 1 or 2 in which the anti-C3b(i) antibody is a monoclonal antibody.

7. The method of Claim 1 or 2 further comprising administering IgM antibody or IgG antibody.

8. The method Claim 1 or 2 further comprising administering one or more complement components.

9. The method of Claim 5 in which the effector cell is selected from the group consisting of: lymphocytes, monocytes, macrophages, dendritic cells, neutrophils, natural killer cells and erythrocytes.

10. The method of Claim 5 in which the effector cell is an erythrocyte.

11. The method of Claim 5 in which the antigen is selected from the group consisting of: CR1, CR2, CR3, CR4, CD16, CD32, CD64 and CD89.

12. The method of Claim 5 wherein the bispecific antibody is bound *ex vivo* to the effector cell.

13. The method of Claim 1 or 2 in which the antibody is conjugated to a therapeutic agent.

14. The method of Claim 1 or 2 further comprising administering IgM or IgG antibody and one or more complement components.

15. The method of Claim 1 or 2 in which the antibody is conjugated to a detectable agent.

16. The method of Claim 1 or 2 further comprising administering plasma.

17. The method of Claim 1 or 2 further comprising administering one or more antibodies immunospecific for a cancer cell antigen.

18. The method of Claim 1 or 2 further comprising administering one or more antibodies immunospecific for a cancer cell antigen and one or more complement components.

19. The method of Claim 6 in which the monoclonal antibody is a human or humanized monoclonal antibody.

20. The method of claim 1 or 2 in which the animal is a human.

21. The method of claim 7 in which the animal is a human.

22. The method of claim 17 in which the animal is a human.

Add A6

Add A4 B5 B35